A research team headed by James Zou at Stanford University has published a study in Science, presenting a cutting-edge multi-agent AI system named Virtual Biotech. This innovative system is designed to mirror the organizational structure of a real-world biotechnology company, with a virtual Chief Scientific Officer at its helm, orchestrating operations. It encompasses a core group of agents and can dynamically scale up to tens of thousands of temporary parallel agents as needed, spanning the entire drug development spectrum—from target identification and safety evaluation to drug formulation selection and clinical research.

Virtual Biotech boasts seamless integration with professional biomedical databases and analytical tools, ensuring comprehensive data access and analysis. A key feature of the system is its independent review agent, which meticulously verifies results to maintain accuracy and reliability. During testing, the system demonstrated remarkable efficiency by organizing over 37,000 clinical trial data items in a mere 6 hours. Furthermore, within less than 24 hours and at a minimal cost of approximately $46, it autonomously proposed a B7-H3 ADC treatment strategy for lung cancer. This strategy subsequently earned Breakthrough Therapy designation from the FDA, underscoring its potential impact.

Moreover, Virtual Biotech has the capability to scrutinize failed clinical trials, pinpointing issues such as insufficient patient stratification, thereby contributing to the refinement of future research endeavors. This platform represents an evolution of the team's prior multi-AI agent scientific research framework, Virtual Lab, expanding its capabilities and applications.

The code for Virtual Biotech, along with an interactive website, has been made publicly accessible, fostering transparency and collaboration within the scientific community. Looking ahead, the team intends to validate candidate targets proposed by the system in real-world laboratory settings, further bridging the gap between AI-driven innovation and practical medical advancements.